Cargando…

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine-based treatment to the use of targeted agents, which include sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, everolimus, pazopanib, and most recently, axiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, In-Chang, Chung, Jinsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332131/
https://www.ncbi.nlm.nih.gov/pubmed/22536463
http://dx.doi.org/10.4111/kju.2012.53.4.217
_version_ 1782230179802775552
author Cho, In-Chang
Chung, Jinsoo
author_facet Cho, In-Chang
Chung, Jinsoo
author_sort Cho, In-Chang
collection PubMed
description The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine-based treatment to the use of targeted agents, which include sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, everolimus, pazopanib, and most recently, axitinib. Improved understanding of the molecular pathways implicated in the pathogenesis of RCC has led to the development of specific targeted therapies for treating the disease. In Korea, it has been 5 years since targeted therapy became available for mRCC. Thus, we now have broader and better therapeutic options at hand, leading to a significantly improved prognosis for patients with mRCC. However, the treatment of mRCC remains a challenge and a major health problem. Many questions remain on the efficacy of combination treatments and on the best methods for achieving complete remission. Additional studies are needed to optimize the use of these agents by identifying those patients who would most benefit and by elucidating the best means of delivering these agents, either in combination or as sequential single agents. Furthermore, numerous ongoing research activities aim at improving the benefits of the new compounds in the metastatic situation or their application in the early phase of the disease. This review introduces what is currently known regarding the fundamental biology that underlies clear cell RCC, summarizes the clinical evidence supporting the benefits of targeted agents in mRCC treatment, discusses survival endpoints used in pivotal clinical trials, and outlines future research directions.
format Online
Article
Text
id pubmed-3332131
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Urological Association
record_format MEDLINE/PubMed
spelling pubmed-33321312012-04-25 Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma Cho, In-Chang Chung, Jinsoo Korean J Urol Review Article The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine-based treatment to the use of targeted agents, which include sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, everolimus, pazopanib, and most recently, axitinib. Improved understanding of the molecular pathways implicated in the pathogenesis of RCC has led to the development of specific targeted therapies for treating the disease. In Korea, it has been 5 years since targeted therapy became available for mRCC. Thus, we now have broader and better therapeutic options at hand, leading to a significantly improved prognosis for patients with mRCC. However, the treatment of mRCC remains a challenge and a major health problem. Many questions remain on the efficacy of combination treatments and on the best methods for achieving complete remission. Additional studies are needed to optimize the use of these agents by identifying those patients who would most benefit and by elucidating the best means of delivering these agents, either in combination or as sequential single agents. Furthermore, numerous ongoing research activities aim at improving the benefits of the new compounds in the metastatic situation or their application in the early phase of the disease. This review introduces what is currently known regarding the fundamental biology that underlies clear cell RCC, summarizes the clinical evidence supporting the benefits of targeted agents in mRCC treatment, discusses survival endpoints used in pivotal clinical trials, and outlines future research directions. The Korean Urological Association 2012-04 2012-04-18 /pmc/articles/PMC3332131/ /pubmed/22536463 http://dx.doi.org/10.4111/kju.2012.53.4.217 Text en © The Korean Urological Association, 2012 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Cho, In-Chang
Chung, Jinsoo
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
title Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
title_full Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
title_fullStr Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
title_full_unstemmed Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
title_short Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
title_sort current status of targeted therapy for advanced renal cell carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332131/
https://www.ncbi.nlm.nih.gov/pubmed/22536463
http://dx.doi.org/10.4111/kju.2012.53.4.217
work_keys_str_mv AT choinchang currentstatusoftargetedtherapyforadvancedrenalcellcarcinoma
AT chungjinsoo currentstatusoftargetedtherapyforadvancedrenalcellcarcinoma